JAMP-Pregabalin 50 mg: One lot recalled as some bottles may contain 150 mg capsules

Issue

JAMP Pharma Corp. is recalling one lot of JAMP-Pregabalin because some manufacturer bottles labelled to contain 50 mg capsules may contain 150 mg capsules. This could lead to patients receiving a much larger dose than prescribed, which could result in an overdose and pose serious, potentially fatal health risks. JAMP-Pregabalin is a prescription drug used in adults to treat pain caused by nerve damage due to diabetes, shingles or spinal cord injury. It is also used to treat pain associated with fibromyalgia. Taking too much pregabalin or suddenly increasing the dose could potentially lead to an overdose, which can be life-threatening. Symptoms of pregabalin overdose may include: sudden mood changes, sleepiness, confusion, depression, agitation, restlessness and seizures. Additionally, taking too much pregabalin while taking drugs that act on the central nervous system, including opioids, has been associated with heart electrical problems, seizures and death. Patients should not abruptly stop taking pregabalin, as this may result in withdrawal symptoms including insomnia, nausea, headache, anxiety, excessive sweating, diarrhea, and convulsions. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.